We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LEN:NYSELennar Corporation Analysis

Data as of 2026-03-10 - not real-time

$98.72

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Lennar (LEN) is trading at $98.72, just above its technical support of $96.40 and well below its 20‑day SMA of $112.91, indicating short‑term weakness. The RSI of 26.8 signals oversold conditions, while a bearish MACD (line –3.74 vs signal –1.86) suggests momentum remains negative. Fundamentals show a 5.8% revenue contraction, modest profit margin of 6.1%, and a debt‑to‑equity ratio of 27.7%, but the company retains a solid cash buffer ($9.9 B) and a 2% dividend with a 25% payout ratio. Analyst consensus is a “hold” with a median price target of $107.5, implying roughly 9% upside, yet recent earnings commentary points to margin pressure from aggressive sales incentives.
Given the high 30‑day volatility (33.2%) and a beta of 0.66, LEN is less correlated with broader market swings, but the consumer‑cyclical housing sector remains sensitive to macro‑economic shifts. The combination of oversold technical signals, modest upside to target, and a sustainable dividend supports a cautious stance, while the lack of near‑term catalysts and ongoing margin compression temper enthusiasm.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Price near technical support and below short‑term moving averages
  • Oversold RSI but bearish MACD momentum
  • No immediate earnings catalyst

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Analyst median target price suggests ~9% upside
  • Revenue decline and margin pressure from incentives
  • Solid cash position and sustainable dividend

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Long‑run housing demand and favorable demographic trends
  • Undervalued valuation relative to fair‑value and target price
  • Stable dividend yield and low beta reducing market risk

Key Metrics & Analysis

Financial Health

Revenue Growth-5.80%
Profit Margin6.08%
P/E Ratio12.4
ROE8.41%
ROA4.72%
Debt/Equity27.73
P/B Ratio1.1
Op. Cash Flow$216.8M
Free Cash Flow$12.2B

Technical Analysis

TrendNeutral
RSI26.8
Support$96.40
Resistance$124.16
MA 20$112.91
MA 50$112.41
MA 200$118.48
MACDBearish
VolumeIncreasing
Fear & Greed Index76.91

Valuation

Fair Value$696.77
Target Price$108.21
Upside/Downside9.62%
GradeUndervalued
TypeBlend
Dividend Yield2.00%

Risk Assessment

Beta0.66
Volatility33.24%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.